ARROW® UltraQuik™ Peripheral Nerve Block Needles Receive FDA 510(k) Clearance

  ARROW® UltraQuik™ Peripheral Nerve Block Needles Receive FDA 510(k)

Business Wire

LIMERICK, Pa. -- January 22, 2013

Teleflex Incorporated (NYSE: TFX) today announced that the ARROW UltraQuik
peripheral nerve block (PNB) needles have received 510(k) clearance from the
U.S. Food and Drug Administration (FDA).

ARROW UltraQuik peripheral nerve block needles are designed to help increase
overall block success for clinicians who use ultrasound-guidance when
performing single-injection PNBs. UltraQuik needles maintain many of the same
clinician-inspired features of the ARROW^® StimuQuik^® ECHO needles, including
five grooved rings at the distal tip of the needle to help clinicians identify
the needle tip under ultrasound.

"Teleflex is pleased to add the ARROW UltraQuik to our line of peripheral
nerve block needles," said Cary Vance, President, Anesthesia and Respiratory
Division. "The ARROW UltraQuik, StimuQuik and StimuQuik ECHO needles allow us
to now offer products to clinicians performing peripheral nerve blocks,
whether they use ultrasound only, nerve stimulation only, or a combined

For more information on Teleflex® anesthesia products and educational
programs, visit

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range
of procedures in critical care and surgery. Our mission is to provide
solutions that enable healthcare providers to improve outcomes and enhance
patient and provider safety. Headquartered in Limerick, PA, Teleflex employs
approximately 11,100 people worldwide and serves healthcare providers in more
than 130 countries. Additional information about Teleflex can be obtained from
the company's website at

Forward-Looking Statements

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any forward-looking
statements contained herein are based on our management's current beliefs and
expectations, but are subject to a number of risks, uncertainties and changes
in circumstances, which may cause actual results or company actions to differ
materially from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report on
Form 10-K.

Arrow, StimuQuik, Teleflex, and UltraQuik are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates. ©2013 Teleflex
Incorporated. All rights reserved. 2013-1635.


Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
Press spacebar to pause and continue. Press esc to stop.